Most importantly, the combination of two clinical drugs (CDK4/6 inhibitor Palbociclib and XPO1 inhibitor KPT‐330) effectively inhibited BLBC cell proliferation and tumor growth (Figure 6H). Here, XPO1 is linked to neoplasm.